237 related articles for article (PubMed ID: 20803222)
1. Guidelines for the control of nausea and vomiting with chemotherapy of low or minimal emetic potential.
Olver I; Clark-Snow RA; Ballatori E; Espersen BT; Bria E; Jordan K
Support Care Cancer; 2011 Mar; 19 Suppl 1():S33-6. PubMed ID: 20803222
[TBL] [Abstract][Full Text] [Related]
2. 2016 Updated MASCC/ESMO Consensus Recommendations: Controlling nausea and vomiting with chemotherapy of low or minimal emetic potential.
Olver I; Ruhlmann CH; Jahn F; Schwartzberg L; Rapoport B; Rittenberg CN; Clark-Snow R
Support Care Cancer; 2017 Jan; 25(1):297-301. PubMed ID: 27572335
[TBL] [Abstract][Full Text] [Related]
3. 2023 updated MASCC/ESMO Consensus recommendations: Prevention of nausea and vomiting following moderately emetic risk antineoplastic agents.
Scotté F; Schwartzberg L; Iihara H; Aapro M; Gralla R; Hesketh PJ; Jordan K; Chow R; Herrstedt J
Support Care Cancer; 2023 Dec; 32(1):45. PubMed ID: 38114821
[TBL] [Abstract][Full Text] [Related]
4. [Prophylaxis of chemotherapy-induced vomiting and nausea].
Tóth J; Szántó J
Magy Onkol; 2008 Dec; 52(4):391-4. PubMed ID: 19068468
[TBL] [Abstract][Full Text] [Related]
5. Practice Patterns for Prevention of Chemotherapy-Induced Nausea and Vomiting and Antiemetic Guideline Adherence Based on Real-World Prescribing Data.
Aapro M; Scotté F; Escobar Y; Celio L; Berman R; Franceschetti A; Bell D; Jordan K
Oncologist; 2021 Jun; 26(6):e1073-e1082. PubMed ID: 33555084
[TBL] [Abstract][Full Text] [Related]
6. 5-Hydroxytryptamine-3 receptor antagonist and dexamethasone as prophylaxis for chemotherapy-induced nausea and vomiting during moderately emetic chemotherapy for solid tumors: a multicenter, prospective, observational study.
Matsui R; Suzuki K; Takiguchi T; Nishio M; Koike T; Hayashi T; Seto T; Kogure Y; Nogami N; Fujiwara K; Kaneda H; Harada T; Shimizu S; Kimura M; Kenmotsu H; Shimokawa M; Goto K
BMC Pharmacol Toxicol; 2020 Oct; 21(1):72. PubMed ID: 33023657
[TBL] [Abstract][Full Text] [Related]
7. Consensus recommendations for the prevention of vomiting and nausea following high-emetic-risk chemotherapy.
Kris MG; Tonato M; Bria E; Ballatori E; Espersen B; Herrstedt J; Rittenberg C; Einhorn LH; Grunberg S; Saito M; Morrow G; Hesketh P
Support Care Cancer; 2011 Mar; 19 Suppl 1():S25-32. PubMed ID: 20803039
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity--state of the art.
Grunberg SM; Warr D; Gralla RJ; Rapoport BL; Hesketh PJ; Jordan K; Espersen BT
Support Care Cancer; 2011 Mar; 19 Suppl 1():S43-7. PubMed ID: 20972805
[TBL] [Abstract][Full Text] [Related]
9. 2023 updated MASCC/ESMO consensus recommendations: controlling nausea and vomiting with chemotherapy of low or minimal emetic potential.
Olver I; Clark-Snow R; Ruhlmann CH; Garcia-Del-Barrio MA; Schwartzberg L; Rapoport BL; Jahn F
Support Care Cancer; 2023 Dec; 32(1):37. PubMed ID: 38110581
[TBL] [Abstract][Full Text] [Related]
10. Antiemetic research: future directions.
Olver I; Molassiotis A; Aapro M; Herrstedt J; Grunberg S; Morrow G
Support Care Cancer; 2011 Mar; 19 Suppl 1():S49-55. PubMed ID: 21063733
[TBL] [Abstract][Full Text] [Related]
11. Prescription of Prophylactic Antiemetic Drugs for Patients Receiving Chemotherapy With Minimal and Low Emetic Risk.
Okuyama A; Nakamura F; Higashi T
JAMA Oncol; 2017 Mar; 3(3):344-350. PubMed ID: 27812688
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of Adherence to Antiemetic Treatment Guidelines in Patients With Chemotherapy-Induced Nausea and Vomiting in Teaching Hospitals in Tehran.
Nikbakht Z; Rajabi M; Shahrasbi A; Roohi E; Hashemian F
J Cancer Educ; 2021 Oct; 36(5):1022-1029. PubMed ID: 31955393
[TBL] [Abstract][Full Text] [Related]
13. Japanese Society of Clinical Oncology clinical practice guidelines 2010 for antiemesis in oncology: executive summary.
Takeuchi H; Saeki T; Aiba K; Tamura K; Aogi K; Eguchi K; Okita K; Kagami Y; Tanaka R; Nakagawa K; Fujii H; Boku N; Wada M; Akechi T; Udagawa Y; Okawa Y; Onozawa Y; Sasaki H; Shima Y; Shimoyama N; Takeda M; Nishidate T; Yamamoto A; Ikeda T; Hirata K
Int J Clin Oncol; 2016 Feb; 21(1):1-12. PubMed ID: 26081252
[TBL] [Abstract][Full Text] [Related]
14. Delayed emesis: moderately emetogenic chemotherapy (single-day chemotherapy regimens only).
Roila F; Warr D; Aapro M; Clark-Snow RA; Einhorn L; Gralla RJ; Herrstedt J; Saito M; Tonato M
Support Care Cancer; 2011 Mar; 19 Suppl 1():S57-62. PubMed ID: 21132332
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of triplet regimen antiemetic therapy for chemotherapy-induced nausea and vomiting (CINV) in bone and soft tissue sarcoma patients receiving highly emetogenic chemotherapy, and an efficacy comparison of single-shot palonosetron and consecutive-day granisetron for CINV in a randomized, single-blinded crossover study.
Kimura H; Yamamoto N; Shirai T; Nishida H; Hayashi K; Tanzawa Y; Takeuchi A; Igarashi K; Inatani H; Shimozaki S; Kato T; Aoki Y; Higuchi T; Tsuchiya H
Cancer Med; 2015 Mar; 4(3):333-41. PubMed ID: 25533447
[TBL] [Abstract][Full Text] [Related]
16. Antiemetics: an update and the MASCC guidelines applied in clinical practice.
Herrstedt J
Nat Clin Pract Oncol; 2008 Jan; 5(1):32-43. PubMed ID: 18097455
[TBL] [Abstract][Full Text] [Related]
17. Antiemetics: American Society of Clinical Oncology clinical practice guideline update.
Basch E; Prestrud AA; Hesketh PJ; Kris MG; Feyer PC; Somerfield MR; Chesney M; Clark-Snow RA; Flaherty AM; Freundlich B; Morrow G; Rao KV; Schwartz RN; Lyman GH;
J Clin Oncol; 2011 Nov; 29(31):4189-98. PubMed ID: 21947834
[TBL] [Abstract][Full Text] [Related]
18. Consensus proposals for the prevention of acute and delayed vomiting and nausea following high-emetic-risk chemotherapy.
Kris MG; Hesketh PJ; Herrstedt J; Rittenberg C; Einhorn LH; Grunberg S; Koeller J; Olver I; Borjeson S; Ballatori E
Support Care Cancer; 2005 Feb; 13(2):85-96. PubMed ID: 15565277
[TBL] [Abstract][Full Text] [Related]
19. Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update.
Hesketh PJ; Kris MG; Basch E; Bohlke K; Barbour SY; Clark-Snow RA; Danso MA; Dennis K; Dupuis LL; Dusetzina SB; Eng C; Feyer PC; Jordan K; Noonan K; Sparacio D; Somerfield MR; Lyman GH
J Clin Oncol; 2017 Oct; 35(28):3240-3261. PubMed ID: 28759346
[TBL] [Abstract][Full Text] [Related]
20. Chemotherapy-induced nausea and vomiting in Italian cancer centers: results of CINVDAY, a prospective, multicenter study.
De Tursi M; Carella C; Tomao S; Cinieri S; Lorusso V; Marchetti P; Vecchio S; Sansoni E; Contu A; Adamo V; Silvestris N; Nuzzo A; Rosti G; Ravaioli A; Danova M; Tonini G; Passalacqua R; Cruciani G; Faedi M; Spada M; De Laurentiis M; Amoroso D; Tomao F; Sperduti I; Grassadonia A; Tinari N; Natoli C; Iacobelli S;
Tumori; 2014; 100(6):e309-13. PubMed ID: 25688518
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
